BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Telegram Restored on Apple App Store After Temporary Removal 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Apple Restores Telegram to App Store After Content Policy Violation 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
VANCOUVER, British Columbia, March 31, 2018 -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today recognizes World Lipodystrophy Day.
Chief Operating Officer Jeff Hackman said, "We are honored to join together with the patient community in support of World Lipodystrophy Day, with a goal of increasing awareness of this serious rare disease. Awareness and education are important initiatives which help recognition and diagnosis of the disease.”
Lipodystrophy is a group of rare diseases characterized by a lack of fat tissue. In some patients, it is genetic, and in others it may be acquired. It can be characterized by a widespread lack of fat tissue under the skin (generalized lipodystrophy) or limited lack of fat tissue (partial lipodystrophy). This loss of fat tissue causes a deficit in the hormone leptin, leading to some severe metabolic complications.
“We are passionate about providing support for lipodystrophy patients and their caregivers, and we advocate tirelessly to increase understanding of the disease and further research into lipodystrophy. World Lipodystrophy Day is an important initiative that increases public awareness to help us achieve these goals on behalf of patients living with this serious and often unknown disease,” said Andra Stratton, president and co-founder of Lipodystrophy United.
“The challenges that patients living with lipodystrophy and their families face are significant. World Lipodystrophy Day helps us to raise awareness and understanding so that we can improve diagnosis and care for those affected by this rare disease globally,” said Naca Eulalia Perez de Tudela Cánovas, president and founder of the international organization Association of Families Affected by Lipodystrophies in Spain, Europe & Latin America.
To learn more about lipodystrophy, visit www.lipodystrophyunited.org, www.aelip.es, or www.lipodystrophy.co.uk.
CONTACT:
Novelion Therapeutics Inc.
Amanda Murphy
Director, Investor Relations & Corporate Communications
857-242-5024
